Predictive Factors of Tumor Control in Patients with Well-differentiated Digestive Endocrine Carcinomas (WDEC) Treated with Lanreotide Abstract #219

Introduction: Somatostatin analogues (SSA) are indicated in the control of secretory symptoms of digestive endocrine tumors. The antiproliferative effect of SSA was recently demonstrated (Rinke et al, JCO 2009).
Aim(s): To identify factors associated with tumor control in a group of patients with WDEC treated with lanreotide.
Materials and methods: Retrospective study in 68 patients with WDEC treated with lanreotide alone, primary endpoint: PFS. Uni- and multivariate analysis on age, gender, discovery mode, origin of the primary tumor, metastatic spread, Ki-67 index, grade of uptake on SRS, pre-treatment evolutivity, extent of liver involvement, resection of the primary, and tumor markers.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Pr Philippe Ruszniewski

To read results and conclusion, please login ...

Further abstracts you may be interested in

#130 Lanreotide Autogel for malignant carcinoid syndrome: an 8-year experience
Introduction: Somatostatin analogues provide symptomatic relief in carcinoid syndrome and recently have been shown to inhibit tumor growth in metastatic gastroenteropancreatic neuroendocrine tumors (NETs). Lanreotide compounds are reported to have similar efficacy to Octreotide compounds. There is limited long-term data available on Lanreoitde Autogel.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohid S Khan
#297 Hepatic Arterial Embolization v. Chemoembolization in Patients with Liver Metastases of Digestive Neuroendocrine Tumors
Introduction: Promising results have been reported using hepatic arterial chemoembolization (CE) or embolization (E) alone in patients with liver metastases of DET, but these modalities have not been compared.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Pr Philippe Ruszniewski
#858 Metastatic Pancreatic Neuroendocrine Tumors with Ectopic Cushing Syndrome: Could Everolimus Be a Safe Therapeutic Option?
Introduction: Everolimus(E) has proved effective in prolonging PFS in advanced P-NETs. As E is a substrate of CYP3A4 co-administration with ketoconazole (k), a strong inhibitor of CYP3A4 used to control hypercortisolism, should be avoided.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Clinical cases/reports
Presenting Author: Maria Vittoria Davì
#896 Grading of Metastases in Digestive Neuroendocrine Tumors (NET): Interest for Clinical Management?
Introduction: Therapeutic strategy of NETs is highly dependent on tumor classification according to the WHO system. NETs are frequently classified based on the histological characteristics of the primary tumor associated with the ENETS grading, even for patients with metastases.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Pathology, grading, staging
Presenting Author: Dr Marie-Françoise Heymann
Keywords: NET, grading
#2682 PAK4-NAMPT Dual Inhibition as a Novel Strategy for Therapy Resistant Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (PNET) remain an unmet clinical need. In this study, we show that targeting both nicotinamide phosphoribosyltransferase (NAMPT) and p21-activated kinase 4 (PAK4) could become a synthetic lethal strategy for PNET.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Ph.D. Candidate Gabriel Mpilla
Authors: Mpilla G, Aboukameel A, Muqbil I, Kim S, ...